Aim: Severe acute respiratory syndrome coronavirus
(SARS-CoV-2) is a novel coronavirus which has infected millions of people
across the globe in the form of a deadly pandemic. Safe and efficacious
vaccines are needed urgently to prevent disease in the healthy population or at
least decrease the intensity of illness post vaccination.
Aim: To assess the
post vaccination side effects among groups of individuals so that an effective
vaccine can be proposed according to the individuals and thus avoiding
reactogenicity, both systemic and local.
Methods: A prospective
study was conducted with the help of a web-based questionnaire (among health
care workers) which used snowball sampling strategy and assigned persons aged
≥25-65 years, who received an intramuscular injection of the vaccine
manufactured by Oxford-AstraZeneca. Safety and side effects were observed over
a period of 15-20 days post vaccination to obtain results.
Results: A total of 564 participants took part in the survey who
received the vaccine via intramuscular route. Both systemic and local
reactogenicity were recorded. Of the respondents, 280 (49.6%) people reported
fever, 322 (57.18%) had pain, 89 (15.77%) had swelling and 53 (9.3%) had
redness at the injection site. Total of 368 (65.2%) individuals suffered from
body aches of whom 324 (57.4%) also reported headaches.
Conclusion: Assessing the post vaccination symptoms, side effects
and complications of AstraZeneca among different individuals helped in
providing crucial and important information regarding the efficacy, safety and
nature of the vaccine.
Keywords: Covid-19, pandemic, vaccines, reactogenicity